MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
GlobeNewswire
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company..